There is a currently a phase I/2 trial (NCT00458536) that is studying the safety of a dendritic cell tumor fusion vaccine in combination with granulocyte macrophage colony-stimulating factor vaccine (GM-CSF) in patients with untreated metastatic RCC for whom a cytoreductive nephrectomy is planned. Here, CSF2 is linked to renal cell carcinoma.